Imaging Angiogenesis in Atherosclerosis in Large Arteries with 68Ga-NODAGA-RGD PET/CT: Relationship with Clinical Atherosclerotic Cardiovascular Disease

Matthieu DIETZ (Matthieu.dietz@chuv.ch)
CHUV: Centre Hospitalier Universitaire Vaudois
https://orcid.org/0000-0001-6041-2531

Christel H. Kamani
CHUV: Centre Hospitalier Universitaire Vaudois

Emmanuel Deshayes
Montpellier Cancer Research Institute: Institut de Recherche en Cancerologie de Montpellier

Vincent Dunet
CHUV: Centre Hospitalier Universitaire Vaudois

Periklis Mitsakis
CHUV: Centre Hospitalier Universitaire Vaudois

George Coukos
CHUV: Centre Hospitalier Universitaire Vaudois

Marie Nicod Lalonde
CHUV: Centre Hospitalier Universitaire Vaudois

Niklaus Schaefer
CHUV: Centre Hospitalier Universitaire Vaudois

John O. Prior
CHUV: Centre Hospitalier Universitaire Vaudois

Research Article

Keywords: Atherosclerosis, angiogenesis, 68Ga-NODAGA-RGD, PET/CT

DOI: https://doi.org/10.21203/rs.3.rs-508079/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Integrin alpha-V-beta-3 (αvβ3) pathway is involved in intraplaque angiogenesis and inflammation and represents a promising target for molecular imaging in cardiovascular diseases such as atherosclerosis. The aim of this study was to assess the clinical correlates of arterial wall accumulation of $^{68}$Ga-NODAGA-RGD, a specific αvβ3 integrin ligand for PET.

Materials and methods

The data of 44 patients who underwent $^{68}$Ga-NODAGA-RGD PET/CT scans were retrospectively analyzed. Tracer accumulation in the vessel wall of major arteries was analyzed semi-quantitatively by blood-pool-corrected target-to-background ratios. Tracer uptake was compared with clinically documented atherosclerotic cardiovascular disease, cardiovascular risk factors and calcified plaque burden. Data were compared using the Mann-Whitney U test and Spearman correlation.

Results

$^{68}$Ga-NODAGA-RGD arterial uptake was significantly higher in patients with previous clinically documented atherosclerotic cardiovascular disease (mean TBR 2.44 [2.03-2.55] vs. 1.81 [1.56-1.96], $p = 0.001$) and showed a significant correlation with prior cardiovascular or cerebrovascular event ($r = 0.34, p = 0.024$), BMI ($r = 0.38, p = 0.01$), plaque burden ($r = 0.31, p = 0.04$), and hypercholesterolemia ($r = 0.31, p = 0.04$).

Conclusions

$^{68}$Ga-NODAGA-RGD holds promise as a non-invasive marker of disease activity in atherosclerosis, providing information about intraplaque angiogenesis.

Introduction

Cardiovascular atherosclerotic disease is the leading cause of death worldwide (1). Atherosclerosis is a systemic condition consisting of the accumulation of fatty and/or fibrous material in the subendothelial space (intima) of medium and large-sized arteries. This process results in the formation of progressive inflammatory plaques that represent the hallmark lesion (2). The development of atherosclerosis is an intricate process of cellular alterations over a prolonged period. In atherosclerotic lesions, the combination of macrophage infiltration and apoptotic death together with hypoxia-induced necrosis is thought to promote neovascularization (3). Angiogenesis within the vessel wall is comprised of a network of capillaries that arise from the adventitial vasa vasorum and extend into the intimal layer. These capillaries are thought to be important regulators of plaque growth and as a key factor in lesion
instability. Increased density of capillaries is associated with intraplaque hemorrhage and plaque rupture (3, 4).

Combined positron emission tomography and computed tomography (PET/CT) is a non-invasive hybrid imaging technique that could potentially be used to measure inflammatory activity within the vasculature (5). Integrins αvβ3 are transmembrane glycoproteins that are involved in the migration of activated endothelial cells during the formation of new vessels. Integrins αvβ3 are expressed in endothelial cells, medial and some intimal smooth muscle cells. Expression of αvβ3 integrin was also found in CD68-positive macrophages in the shoulder of advanced plaques and in the perimeter of the necrotic core of atherosclerotic lesions (6). Integrin αvβ3 contains a distinctive RGD-amino acid sequence (arginine-glycine-aspartate) in the cell-ligand interaction site. Hence, a few RGD-based PET agents have been tested for imaging integrin in atherosclerosis, mainly in preclinical models (7–11), and in two recent clinical evaluations (12, 13).

68Ga-NODAGA-RGD is an emerging RGD-based PET radiotracer with strong affinity for the αvβ3 integrin (14, 15). We hypothesized that 68Ga-NODAGA-RGD may act as an imaging marker of inflammation and angiogenesis in atherosclerosis. The purpose of this study was to examine the relationship between arterial wall 68Ga-NODAGA-RGD uptake in large arteries and the incidence of atherosclerotic cardiovascular diseases.

Material And Methods

Patients

The population of this retrospective study consisted of consecutive patients who had been referred to our institution for a 68Ga-NODAGA-RGD PET/CT within clinical study protocols. Included in this analysis were trials assessing tumoral angiogenesis (NCT02666547, NCT03475134), cardiac lesions angiogenesis (NCT03809689), and inflammatory atheromatous plaques in the carotid arteries (NCT01608516) (14, 15). Patients were included if they underwent a 68Ga-NODAGA-RGD PET/CT from vertex to mid-thigh. Patients could not be included if they did explicitly refuse the retrospective use of their data for research. All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its last amendments or comparable ethical standards. The Ethics Committee Vaud (CER-VD) approved this retrospective study protocol (CER-VD #2018_01513) and waived the need for patient informed consent for the study analysis.

Clinical data

Clinical data were collected retrospectively from the medical records of the patients. History of atherosclerotic cardiovascular disease (ASCVD) was collected, according to the strict same definitions as listed by Mach et al. (16), including previous acute coronary syndrome (myocardial infarction or unstable angina), stable angina, coronary revascularization (percutaneous coronary intervention, coronary artery
bypass graft surgery, and other arterial revascularization procedures), stroke and transient ischemic attack, and peripheral arterial disease. Subjects with any type of clinically documented ASCVD were classified into the ASCVD group. Subjects with no clinically documented ASCVD were classified into the control group. Cardiovascular risk factors including age, sex, body mass index (BMI), arterial hypertension, hypercholesterolemia, smoking (current or former), and diabetes mellitus were also collected for every subject. Because of the potential influence of statins on expression of vascular endothelial growth factor on monocytes, treatments with statins were also recorded (17).

**Image acquisitions**

$^{68}$Ga-NODAGA-RGD PET/CT were performed at our hospital. Pregnancy was excluded in women of childbearing age before each PET/CT. $^{68}$Ga-NODAGA-RGD PET/CT images were acquired 63 [59–71] minutes after intravenous administration of 190 [175–210] MBq of $^{68}$Ga-NODAGA-RGD in an antecubital vein followed by 10 mL of 0.9% NaCl solution.

Images were acquired on a Discovery 690 TOF (GE Healthcare, Waukesha, WI, USA), or a Biograph Vision 600 (Siemens Medical Solutions, Knoxville, USA) PET/CT. Acquisitions were performed with 3 min per bed position (Discovery), or a continuous flow mode (Biograph Vision). PET data were reconstructed using OSEM (Discovery: 3 iterations, 16 subsets; Biograph Vision: 4 iterations, 5 subsets). Head to mid-thigh unenhanced CT was acquired for attenuation correction (Discovery: 120 kV, 40 mA, 0.8 s/rotation, pitch 0.9; Biograph Vision: 100 kV, 40 mA, 0.5 s/rotation, pitch 0.8).

**Image analysis**

Transaxial PET, CT, and fused $^{68}$Ga-NODAGA-RGD PET/CT images were analyzed both visually and semi-quantitatively on a dedicated workstation (Syngo.Via, VB30 Siemens Healthcare).

$^{68}$ Ga-NODAGA-RGD uptake

Maximal standardized uptake values (SUVmax) for $^{68}$Ga-NODAGA-RGD were measured in the following arterial segments: both common carotid arteries, ascending aorta, aortic arch, descending aorta, abdominal aorta, and both iliac arteries, using a previously validated method (18). Briefly, on axial coregistered PET/CT slices, simple circular regions of interest (ROIs) were placed to cover arterial walls and lumen. For those vessels of greater diameter, 1-cm diameter ROIs were placed along the arterial walls and were slid along the arterial segments to locate the highest SUVmax within the tubular arterial segment, avoiding areas of $^{68}$Ga-NODAGA-RGD spillover. For blood pool SUV measurements, three different 1-cm diameter ROIs were placed in both the mid-lumen of the inferior and superior vena cava, and the SUVmean of the 6 measurements was collected (blood pool activity = average of the 6 SUVmean measurements). SUVmax were then corrected for blood pool activity to provide tissue-to-background ratios (TBR = SUVmax / blood pool activity) measurements, as a measure of arterial tracer uptake (18). The average TBR (mean TBR) was calculated for each patient, considering all assessed segments. TBRaorta was the average of ascending aorta, aortic arch, descending aorta, and abdominal aorta TBR.
measurements. TBRcarotid was the average of both common carotid arteries TBR measurements. TBRiliac was the average of both iliac arteries TBR measurements.

**Plaque burden**

The CT scans were examined for the presence of calcified plaque (high-density mural areas with attenuation >130 Hounsfield units) in the walls of the same arterial segments investigated by PET (19). The amount of calcification was semi-quantitatively ranked according to a previously validated scale (18):

- 0: absent calcified plaque,
- 1: small, calcified plaque covering less than 10% of the vessel circumference,
- 2: calcified plaque involving 10%-25% of the vessel circumference,
- 3: calcified plaque involving 25%-50% of the circumference,
- 4: calcified plaque involving more than 50% of the vessel circumference.

The calcified plaque scores were then summed for the 8 areas (18).

**Statistics**

We assessed the distribution of data with the Shapiro-Wilk test. Continuous parametric variables were expressed as mean ± SD and compared using Student’s t-tests. Nonparametric data were presented as median [interquartile range] and compared using the Mann-Whitney U test. Categorical variables were collected as numbers (n) and percentages (%) and compared using the chi-square test or Fisher exact test. Spearman correlation analysis (\( \rho \)) were used to correlate mean TBR with prior cardiovascular and cerebrovascular event, age, sex, BMI, arterial hypertension, hypercholesterolemia, smoking, and diabetes mellitus. A \( p \) value less than or equal to 0.05 was considered statistically significant. The statistical analysis was performed using R version 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria).

**Results**

**Patients**

In total, fifty-six patients underwent a \(^{68}\text{Ga-NODAGA-RGD}\) PET/CT at our institution and forty-four patients could be included retrospectively. A flowchart of the study design is shown in Fig. 1. Clinical characteristics of the patients are reported in Table 1. Thirty-nine of forty-four patients (89%) were referred within oncologic studies and five of forty-four patients (11%) were referred before carotid endarterectomy.
| Characteristics                                      | Data                      |
|------------------------------------------------------|---------------------------|
| Patients (n)                                         | 44                        |
| Sex (n)                                              |                           |
| Men                                                  | 24 (55%)                  |
| Women                                                | 20 (45%)                  |
| Age (y)                                              | 60 [53–66]                |
| Body mass index (kg/m²)                              | 28 ± 4                    |
| Previous clinically documented ASCVD*               |                           |
| Coronary revascularization†                           | 6 (14%)                   |
| Myocardial infarction                                | 5 (11%)                   |
| Stroke and transient ischemic attack                | 2 (5%)                    |
| Peripheral arterial disease                          | 2 (5%)                    |
| Statin therapy (n)                                   | 8 (18%)                   |
| Cardiovascular risk factors (n)                      |                           |
| Arterial hypertension                                | 13 (30%)                  |
| Hypercholesterolemia                                 | 12 (27%)                  |
| Smoking (current or former)                          | 19 (43%)                  |
| Diabetes mellitus                                    | 4 (9%)                    |
| Type of disease (n)                                   |                           |
| Head and neck tumors                                 | 10 (23%)                  |
| Melanoma                                             | 10 (23%)                  |
| Esophagus carcinoma                                  | 6 (14%)                   |
| Carotid endarterectomy                               | 5 (11%)                   |
| Lung carcinoma                                        | 2 (5%)                    |
| B-cell lymphoma                                       | 2 (5%)                    |

*ASCVD: atherosclerotic cardiovascular disease

†percutaneous coronary intervention or coronary artery bypass graft surgery
Eight of the forty-four patients (18%) had previous myocardial infarction, coronary revascularization, stroke or transient ischemic attack, and/or peripheral arterial disease and were thus classified into the ASCVD group. The thirty-six remaining patients (82%) were classified into the control group. All the five patients referred for carotid endarterectomy were included in the ASCVD group. In this group, the three remaining patients were referred for esophagus, lung, and head and neck tumors. The median age was higher in the ASCVD than in the control group (respectively 64 years [61–72] vs. 59 years [50–65], \( p = 0.059 \), and 7 men of 8 patients; 87%, vs. 17 men of 36 patients; 46%, \( p = 0.054 \)). The ASCVD group included a higher prevalence of hypertension (5 of 8 patients; 62%) as well of hypercholesterolemia (6 of 8 patients; 75%), as compared to the control group (respectively 8 of 36 patients; 23%, \( p = 0.037 \), and 6 of 36 patients; 17%, \( p = 0.003 \)). BMI, smoking and diabetes mellitus did not significantly differ between the two groups (Table 2).
Table 2
Groups Characteristics

| Characteristics   | ASCVD Group n = 8 | Control Group n = 36 | p Between Groups |
|-------------------|-------------------|----------------------|-----------------|
| Age (y)           | 64 [61–72]        | 59 [50–65]           | 0.059           |
| Men               | 7 (87%)           | 17 (46%)             | 0.054           |
| Hypertension      | 5 (62%)           | 8 (23%)              | 0.037           |
| Hypercholesterolemia | 6 (75%)     | 6 (17%)              | 0.003           |
| BMI (kg/m$^2$)    | 30 ± 5            | 28 ± 4               | 0.38            |
| Smoking           | 5 (62%)           | 15 (43%)             | 0.26            |
| Diabetes mellitus | 1 (13%)           | 3 (9%)               | 0.56            |
| Statin medication | 7 (87%)           | 1 (35%)              | < 0.0001        |

ASCVD: atherosclerotic cardiovascular disease

Arterial Wall $^{68}$Ga-NODAGA-RGD uptake and plaque burden

In the entire group of 44 patients, a total of 352 arterial segments were evaluated and statistically analyzed. The PET/CT was acquired on the Discovery PET/CT in 28 patients and on the Biograph Vision PET/CT in the remaining 16 patients. When blood pool activities were compared, no significant difference was found between Discovery PET/CT and Biograph Vision PET/CT acquisitions (1.03 [0.87–1.18] g/mL vs. 1.11 [0.91–1.23] g/mL respectively, $p = 0.25$). Furthermore, when the mean TBR values were compared, there was no difference between patients who had Discovery PET and patients who had Biograph Vision PET (1.77 [1.56–2.10] vs. 1.89 [1.81–2.03] respectively, $p = 0.37$).

The highest TBRs were documented in the descending and abdominal aorta (1.97 [1.72–2.33] and 2.09 [1.69–2.57], respectively) whereas the lowest TBRs were seen in the ascending aorta and common carotid arteries (1.67 [1.39–2.05] and 1.57 [1.31–1.78], respectively). Examples of foci of $^{68}$Ga-NODAGA-RGD arterial uptake are shown in Fig. 2. Calcified plaque scores were the highest in the abdominal aorta (2 [0–4]).

Clinical baseline characteristics and plaque burden correlation

Table 3 shows the correlation of the mean TBR values with clinical baseline characteristics. Prior cardiovascular or cerebrovascular event significantly correlated with $^{68}$Ga-NODAGA-RGD mean TBR ($\rho = 0.34$, $p = 0.024$). $^{68}$Ga-NODAGA-RGD mean TBR also showed a significant correlation with BMI ($\rho = 0.38$, $p = 0.01$), plaque burden ($\rho = 0.31$, $p = 0.04$; Fig. 3), and hypercholesterolemia ($\rho = 0.31$, $p = 0.04$). There
was no significant correlation between $^{68}$Ga-NODAGA-RGD mean TBR and smoking, age, diabetes mellitus and arterial hypertension.

Table 3

| Spearman correlation coefficients | $^{68}$Ga-NODAGA-RGD mean TBR |
|----------------------------------|---------------------------------|
| Prior cardiovascular and cerebrovascular events | 0.34‡ |
| Body mass index | 0.38‡ |
| Plaque burden | 0.31‡ |
| Hypercholesterolemia | 0.31‡ |
| Smoking (current or former) | NS§ |
| Diabetes mellitus | NS§ |
| Arterial hypertension | NS§ |
| Age | NS§ |

‡Significant correlation
§NS: no significance

Quantitative assessment across groups

Quantitative assessment is reported in Table 4. With blood-pool activities being comparable between both groups (0.98 [0.89–1.06] g/mL in the ASCVD group vs. 1.07 [0.89–1.27] g/mL in the control group, $p = 0.39$), mean TBR (Fig. 3) and TBRaorta of $^{68}$Ga-NODAGA-RGD were significantly higher in the ASCVD group as compared to the control group (respectively 2.44 [2.03–2.55] vs. 1.81 [1.56–1.96], $p = 0.001$; and 2.51 [2.31–2.81] vs. 1.86 [1.62–2.04], $p = 0.001$). TBRcarotid and TBRiliac showed a tendency for a higher uptake in the ASCVD group (respectively 1.69 [1.66–2.26] vs. 1.49 [1.27–1.77], $p = 0.08$; and 2.43 [1.68–2.93] vs. 1.92 [1.55–2.14], $p = 0.098$).
### Table 4
Quantitative assessment per Group

| Characteristic                  | ASCVD Group         | Control Group       | \( p \) Between Groups |
|--------------------------------|---------------------|---------------------|------------------------|
| Patients (n)                   | 8                   | 36                  |                        |
| mean TBR                       | 2.44 [2.03–2.55]    | 1.81 [1.56–1.96]    | 0.001                  |
| TBR\(_{\text{aorta}}\)        | 2.51 [2.31–2.81]    | 1.86 [1.62–2.04]    | 0.001                  |
| TBR\(_{\text{carotid}}\)      | 1.69 [1.66–2.26]    | 1.49 [1.27–1.77]    | 0.08                   |
| TBR\(_{\text{iliac}}\)        | 2.43 [1.68–2.93]    | 1.92 [1.55–2.14]    | 0.098                  |
| Blood pool activity (g/mL)     | 0.98 [0.89–1.06]    | 1.07 [0.89–1.27]    | 0.39                   |

\( ^{\text{§}} \)ASCVD: atherosclerotic cardiovascular disease

### Discussion

Our main results are that \(^{68}\)Ga-NODAGA-RGD arterial wall uptake was higher in patients with previous clinically documented ASCVD and correlated with prior cardiovascular or cerebrovascular event and with progressive atherosclerotic plaque burden. Our study would suggest that \(^{68}\)Ga-NODAGA-RGD holds promise as a non-invasive marker of disease activity in atherosclerosis, providing information on key features of high-risk atheroma: inflammation and angiogenesis.

Both inflammation and angiogenesis processes are associated with atheroma progression, plaque rupture and clinical events. The necrotic core in culprit plaques forms as result of increasing inflammation (20). In response to pro-atherogenic stimuli, activated monocytes infiltrated within the intima and differentiate into pro-inflammatory macrophages (21). While progressing, atherosclerotic plaques will develop a lipid-rich or necrotic core, resulting from the apoptosis of the resident pro-inflammatory macrophages (20). Pro-inflammatory macrophage activities within the atherosclerotic plaque lead to the weakening of the protective fibrous cap, mediated by the matrix metalloproteinases, that degrade the extracellular matrix components, predisposing it to rupture (22). Angiogenesis is believed to occur in response to hypoxic conditions within the necrotic core. Indeed, increasing wall thickness during atherosclerosis lead to a reduction of the intravascular oxygen amount, a situation further exacerbated by the increased oxygen consumption of high metabolic activated inflammatory cells within the atherosclerotic plaque (23). Vascular endothelial growth factor further modulates the activation state of the adventitial vasa vasorum endothelial cells to a highly migratory and proliferative state, resulting in neovessels formation towards the base of the plaque (24). Neovessels, arising from the adventitial vasa vasorum, grow into the base of progressive atherosclerotic lesions and provide an alternative entry pathway for monocytes and immune cells. The plaque neovessels are fragile and leaky,
giving rise to local extravasation of plasma proteins and erythrocytes (25). Plaque hemorrhage itself results in a pro-inflammatory response, plaque destabilization and clinical events (3–4).

The use of the PET technique to visualize inflammation in vivo in atherosclerosis in large arteries has been performed with success using tracers such as $^{18}$F-FDG, DOTA-derived somatostatin analogs, or $^{68}$Ga-Pentixafor (18, 26–28). A non-invasive imaging technique that can inform about the activity of two adverse pathological processes, namely inflammation and angiogenesis, might therefore be even more accurate in identifying patients with active high-risk atheroma and potentially predicting risk of rupture. Hence, over the past decade, pre-clinical studies using RGD-based tracers have shown interesting results. In vivo imaging with a small animal PET/CT demonstrated $^{18}$F-galacto-RGD PET signal corresponding to the advanced calcified plaques of the aortic arch region of hypercholesterolemic mice (11). Another study on atherosclerotic mice showed accumulation of $^{68}$Ga-DOTA-RGD into aortic plaques (9). The role of a single photon emission computed tomography $^{99m}$Tc-RGD-based probe in detection of inflammation in mouse models of carotid arteries remodeling has been demonstrated (8). More recently, Su et al. demonstrated a $^{18}$F-labeled RGD preferentially binds to aortic plaque in an ApoE knock out mouse model of atherosclerosis, and Golestani et al. demonstrated a good correlation between $^{18}$F-RGD-K5 uptake and intraplaque neovessels density in carotid endarterectomy specimens (7, 10).

The discussion about the assessment of the atherosclerotic inflammatory activity as a marker of plaque vulnerability relies among others on data showing that non-obstructive coronary artery disease is responsible for most acute coronary syndromes (29, 30). Moreover, some data from catheterization laboratories have shown a high proportion of significant stenosis (> 70% reduction of the coronary lumen) of culprit lesions in patients presenting with ST-segment elevation myocardial infarction (31). In the same line, it has been demonstrated that acute coronary event resulting from obstructive coronary plaque with prior inducible ischemia have better outcome in comparison to acute coronary event from non-obstructive coronary plaque without prior inducible ischemia (32). The protective adaptative changes resulting from the myocardial preconditioning could explain these different outcomes depending on the severity of the artery lumen stenosis and the presence of inducible ischemia prior acute coronary event (33). Nevertheless, these observations further confirm that other criteria above the solely angiographic evaluation of the coronary plaque stenosis should be considered. For this purpose, $^{68}$Ga-NODAGA-RGD PET/CT may aid our pathophysiological understanding of this important condition and help to identify patients at increased risk of adverse cardiovascular events.

Even if some previous literature reported on the role of RGD-based tracers in the imaging of atherosclerosis in humans, it needs to be further established. Thus far, only two recent studies have evaluated the imaging of atherosclerotic lesions with RGD-based PET agents in humans. Beer et al. documented the expression of $\alpha\beta$3 integrin in macrophage infiltrates of plaque specimens obtained from a small sample of patients with high-grade carotid artery stenosis (12). Jenkins et al. have demonstrated that in vivo expression of $\alpha\beta$3 integrin with $^{18}$F-fluciclatide PET/CT in human aortic
atheroma is associated with plaque burden and is increased in patients with recent myocardial infarction (13). Our results are consistent with the promising results of these existing findings.

**Limitations**

Because integrins αvβ3 are expressed in neovessels in plaques but also in CD68-positive macrophages, we are unable to ascertain whether ⁶⁸Ga-NODAGA-RGD was binding preferentially to one or the other of these processes. However, non-selectivity between inflammation and angiogenesis is not necessarily a disadvantage. Both inflammation and angiogenesis are hallmark of unstable atheroma and to combine both processes could be of additional value. There was no histopathological correlation in our study to examine the relation between αvβ3 integrin expression by ⁶⁸Ga-NODAGA-RGD uptake and plaque composition. One other limiting factor is the relatively lower spatial resolution of PET systems compared with other imaging techniques. Further developments in hybrid imaging promise to enhance the scope of molecular imaging. Although the use of ⁶⁸Ga is widespread with ease of use and good availability of this radioisotope through a ⁶⁸Ge/⁶⁸Ga generator, the lower positron energy of ¹⁸F compared to ⁶⁸Ga could potentially improve spatial resolution and reduce blurring effects. Given the difficulty in identifying the exact borders of the coronary arteries on the non-contrast-enhanced and non-gated CT image scans, we did not evaluate the coronary arteries. Furthermore, given the relatively limited number of patients studied using univariate analyses, with a heterogeneous sample, we cannot exclude confounding of our results by other confounding factors.

**Conclusion**

In conclusion, among consecutive patients who had been referred to our institution for a ⁶⁸Ga-NODAGA-RGD PET/CT, ⁶⁸Ga-NODAGA-RGD arterial uptake correlated with prior cardiovascular or cerebrovascular event and plaque burden and was increased in patients with previous clinically documented ASCVD. Although further study is required, our data suggest that RGD-based tracers hold promise as a non-invasive marker of disease activity in atherosclerosis, providing information on inflammation and angiogenesis, with clinical significance.

**Declarations**

**Ethics approval**

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its last amendments or comparable ethical standards. The Ethics Committee Vaud (CER-VD) approved this retrospective study protocol (CER-VD 2018_01513). We included patients who did not explicitly refuse the retrospective use of their data for research, as per local legislation.
Consent for publication

Not applicable.

Conflicts of interest/Competing interests

The authors declare that they have no conflict of interest.

Availability of data and material

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

MD and JOP designed the study. JOP supervised the study. MD, CHK, ED, VD, PM, GK, MNL, NK, JOP contributed to acquisition of clinical and imaging data. MD performed statistical analysis and drafted the manuscript. CHK, ED, VD, PM, GK, MNL, NK, and JOP contributed to critical revision of the report. All authors approved the final draft of the manuscript.

Acknowledgements

The authors would like to thank Christine Geldhof for her help in this study.

The authors are indebted to Swiss Heart Foundation (Bern, Switzerland) for their financial support in developing the Ga-68-RGD radiopharmaceutical.

References

1. Dagenais GR, Leong DP, Rangarajan S, Lanas F, Lopez-Jaramillo P, Gupta R, et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. 2020;395:785-94. https://doi.org/10.1016/S0140-6736(19)32007-0.

2. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5:56. https://doi: 10.1038/s41572-019-0106-z.

3. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25:2054-61. https://doi.org/1161/01.ATV.0000178991.71605.18.
4. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation. 2004;110:2032-8. https://doi.org/10.1161/01.CIR.0000143233.87854.23.

5. Dweck MR, Aikawa E, Newby DE, Tarkin JM, Rudd JH, Narula J, et al. Noninvasive Molecular Imaging of Disease Activity in Atherosclerosis. Circ Res. 2016;119:330-40. https://doi.org/10.1161/CIRCRESAHA.116.307971.

6. Hoshiga M, Alpers CE, Smith LL, Giachelli CM, Schwartz SM. Alpha-v beta-3 integrin expression in normal and atherosclerotic artery. Circ Res. 1995;77:1129-35. https://doi.org/10.1161/01.RES.77.6.1129.

7. Golestani R, Mirfeizi L, Zeebregts CJ, Westra J, de Haas HJ, Glaudemans AW. Feasibility of [18F]-RGD for ex vivo imaging of atherosclerosis in detection of αvβ3 integrin expression. J Nucl Cardiol. 2015;22:1179-86. https://doi.org/10.1007/s12350-014-0061-8.

8. Razavian M, Marfatia R, Mongue-Din H, Tavakoli S, Sinusas AJ, Zhang J, et al. Integrin-targeted imaging of inflammation in vascular remodeling. Arterioscler Thromb Vasc Biol. 2011;31:2820-6. https://doi.org/10.1161/ATVBAHA.111.231654.

9. Haukkala J, Laitinen I, Luoto P, Ivosev P, Wilson I, Karlsen H, et al. 68Ga-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice. Eur J Nucl Med Mol Imaging. 2009;36:2058-67. https://doi.org/10.1007/s00259-009-1220-z.

10. Su H, Gorodny N, Gomez LF, Gangadharmath UB, Mu F, Chen G, et al. Atherosclerotic plaque uptake of a novel integrin tracer 18F-Flotegatide in a mouse model of atherosclerosis. J Nucl Cardiol. 2014;2:553-62. https://doi.org/10.1007/s12350-014-9879-3.

11. Laitinen I, Saraste A, Weidl E, Poethko T, Weber AW, Nekolla SG, et al. Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. Circ Cardiovasc Imaging. 2009;2:331-8. https://doi.org/10.1161/CIRCIMAGING.108.846865.

12. Beer AJ, Pelisek J, Heider P, Saraste A, Reeps C, Metz S, et al. PET/CT imaging of integrin αvβ3 expression in human carotid atherosclerosis. JACC Cardiovasc Imaging. 2014;7:178-87. https://doi.org/10.1016/j.jcmg.2013.12.003.

13. Jenkins WS, Vesey AT, Stirrat C, Connell M, Lucatelli C, Neale A, et al. Cardiac αvβ3 integrin expression following acute myocardial infarction in humans. Heart. 2017;103:607-15. https://doi.org/10.1136/heartjnl-2016-310115.

14. Gnesin S, Cicone F, Mitsakis P, Van der Gucht A, Baechler S, Miralbell R, et al. First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist68Ga-NODAGA-MJ9. EJNMMI Res. 2018;8:108. https://doi.org/10.1186/s13550-018-0462-9.

15. Durante S, Dunet V, Gorostidi F, Mitsakis P, Schaefer N, Delage J, et al. Head and neck tumors angiogenesis imaging with68Ga-NODAGA-RGD in comparison to 18F-FDG PET/CT: a pilot study.
16. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-88.

17. Jaipersad AS, Shantsila E, Blann A, Lip GY. The effect of statin therapy withdrawal on monocyte subsets. Eur J Clin Invest. 2013;43:1307-13. https://doi.org/10.1111/eci.12183.

18. Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50:1611-20. https://doi.org/10.2967/jnumed.109.065151.

19. de Weert TT, Ouhlous M, Meijering E, Zondervan PE, Hendriks JM, van Sambeek MR, et al. In vivo characterization and quantification of atherosclerotic carotid plaque components with multidetector computed tomography and histopathological correlation. Arterioscler Thromb Vasc Biol. 2006;26:2366-72. https://doi.org/10.1161/01.ATV.0000240518.90124.57.

20. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014;114:1852-66. https://doi.org/10.1161/CIRCRESAHA.114.302721.

21. Clinton SK, Underwood R, Hayes L, Sherman ML, Kufe DW, Libby P, et al. Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol. 1992;140:301–16

22. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493–2503. https://doi.org/10.1172/JCI117619.

23. Parathath S, Mick SL, Feig JE, Joaquin V, Grauer L, Habiel DM, et al. Hypoxia is present in murine atherosclerotic plaques and has multiple adverse effects on macrophage lipid metabolism. Circ Res 2011;109:1141–52. https://doi.org/10.1161/CIRCRESAHA.111.246363

24. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425–29. https://doi.org/10.1038/86490.

25. Sluimer JC, Kolodgie FD, Bijnens AP, Maxfield K, Pacheco E, Kutys B, et al. Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J Am Coll Cardiol. 2009;53:1517-27. https://doi.org/10.1016/j.jacc.2008.12.056.

26. Li X, Samnick S, Lapa C, Israel I, Buck AK, Kreissl MC, et al. 68Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with 18F-FDG, calcium burden and risk factors. EJNMMI Res. 2012;2:52. https://doi.org/10.1186/2191-219X-2-52.

27. Weiberg D, Thackeray JT, Daum G, Sohns JM, Kropf S, Wester HJ, et al. Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using 68Ga-Pentixafor PET: Correlation with Cardiovascular Risk Factors and Calcified Plaque Burden. J Nucl Med. 2018;59:266-72. https://doi.org/10.2967/jnumed.117.196485.
28. Malmberg C, Ripa RS, Johnbeck CB, Knigge U, Langer SW, Mortensen J, et al. 64Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with 68Ga-DOTATOC in 60 Patients. J Nucl Med. 2015;56:1895-900. https://doi.org/10.2967/jnumed.115.161216.

29. Hoffmann U, Ferencik M, Udelson JE, Picard MH, Truong QA, Patel MR, et al. Prognostic Value of Noninvasive Cardiovascular Testing in Patients with Stable Chest Pain: Insights from the PROMISE Trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). Circulation 2017;135:2320–32. https://doi.org/10.1161/CIRCULATIONAHA.116.024360.

30. Chang HJ, Lin FY, Lee SE, Andreini D, Bax J, Cademartiri F, et al. Coronary Atherosclerotic Precursors of Acute Coronary Syndromes. J Am Coll Cardiol 2018;71:2511–22. https://doi.org/10.1016/j.jacc.2018.02.079.

31. Manoharan G, Ntalianis A, Muller O, Hamilos M, Sarno G, Melikian N, et al. Severity of Coronary Arterial Stenoses Responsible for Acute Coronary Syndromes. Am J Cardiol 2009;103:1183–88. https://doi.org/10.1016/j.amjcard.2008.

32. Farb A, Burke AP, Tang AL, Liang TY, Mannan P, Smialek J, et al. Coronary plaque erosion without rupture into a lipid core: A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996;93:1354–63. https://doi.org/10.1161/01.cir.93.7.1354

33. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124–36. https://doi.org/10.1161/01.cir.74.5.1124.

---

**Figures**
Patients referred in Centre Hospitalier Universitaire Vaudois from January 2012 to August 2020 for $^{68}$Ga-NODAGA-RGD PET/CT scans within clinical study protocols (n = 56)

Not included (n = 12)
- Patient having expressed explicit refusal for the retrospective use of his data for research
- PET-scan not acquired from vertex to mid-thigh

Patients included for analysis (n = 44)

Patients with clinically documented atherosclerotic cardiovascular disease (ASCVD), including previous acute coronary syndrome, stable angina, coronary revascularization, stroke and transient ischemic attack, and peripheral arterial disease (n = 8)

Patient without clinically documented atherosclerotic cardiovascular disease (n = 36)

Figure 1
Flow chart.
CT (A, D, G), PET/CT (B, E, H), and PET images (C, F, I) in axial views show foci of 68Ga-NODAGA-RGD arterial uptake in partly calcified atherosclerotic lesions (arrows): (A, B, C) in wall of arch aorta in a 62-year-old man who had a myocardial infarction 5 months before PET imaging; (D, E, F) in wall of abdominal aorta in a 54-year-old man who had a transient ischemic attack one week before PET imaging;
(G, H, I) in wall of arch aorta in a 74-year-old woman who had a myocardial infarction 33 months before PET imaging.

Figure 3

A. Scatterplot showing correlation of mean TBR of 68Ga-NODAGA-RGD uptake and calcified plaque scores summation of eight arterial segments on per-patient basis. B. Box plot showing mean TBR for all patients, separated into those with clinically documented atherosclerotic cardiovascular disease (ASCVD group), and those without clinically documented atherosclerotic cardiovascular disease (control group).